Brexanolone is an anti-depressant indicated for the treatment of postpartum depression (PPD) among women.
Brexanolone is indicated for the treatment of postpartum depression (PPD) among women.
End stage renal disease (ESRD)
Brexanolone is available as an Injection: 100 mg/20 mL (5 mg/mL) single-dose vial.
Administer Brexanolone as a continuous intravenous infusion over 60 hours that is 2.5 days.
0 to 4 hrs: Initial dose is 30 mcg/kg/hr
4 to 24 hrs: Increase the dose of Brexanolone to 60 mcg/kg/hr
24 to 52 hrs: Increase the dose of Brexanolone to 90 mcg/kg/hr.
52 to 56 hrs: Decrease dose of Brexanolone to 60 mcg/kg/hr.
56 to 60 hrs: Decrease dose of Brexanolone to 30 mcg/kg/hr.
Before administration dilution is required.
Patients administered Brexanolone infusion should be monitored for excessive sedation and unconsciousness and necessary treatments should be given. Blood oxygen saturation should be monitored by using continuous pulse oximetry equipped with an alarm. Brexanolone infusion should be started early in the day so that excessive sedation can be recognized. During planned non-sleep periods, excessive sedation should be assessed every 2 hours.
Loss of consciousness
Flushing of face or skin
1.During Brexanolone infusion, patients are at an increased risk for the excessive and sudden loss of consciousness and the patients should be monitored for the same.
2.During infusion of the drug patients should have continuous pulse oximetry monitoring. Immediately stop the infusion if pulse oximeter shows low oxygen saturation.
3.During interactions, patients can bring their babies however a caregiver or relative must be present to take care of the baby when the patient is receiving an infusion of brexanolone.
4.Brexanolone is available only through a restricted program under REMS called ZULRESSO REMS as the sudden loss of consciousness and excessive sedation can cause serious harm.
5.Brexanolone can increase the risk of suicidal thoughts or actions in some people 24 years of age and younger. Patients should inform the healthcare provider of any changes especially sudden changes in mood, behavior, thoughts, or feelings, or if they develop suicidal thoughts or actions.
6.Inform the healthcare provider about all the previous or present medical conditions, alcohol consumption, if there are any kidney problems, are pregnant, are breastfeeding, or plan to breastfeed.
7.Inform the healthcare provider if the medications like antidepressants, opioids, and other CNS depressants like benzodiazepines like alprazolam, diazepam or clonazepam are being taken.
8.After receiving brexanolone infusion, do not drive until the feeling of sleepiness is completely gone.
9.Do not consume alcohol while receiving Brexanolone infusion.
Opioids, benzodiazepines (alprazolam, diazepam, clonazepam,etc) as it can increase sedation.
Anti-depressants like citalopram, escitalopram, fluoxetine, sertraline and other similar drugs.
Store undiluted brexanolone at 2 to 8 oC . Do not freeze and protect from sunlight.
FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)
CONSULT A DOCTOR